Full Text
REGD. No. D. L.-33004/99
The Gazette of India
CG-DL-E-23052025-263340
EXTRAORDINARY
PART II-Section 3-Sub-section (ii)
PUBLISHED BY AUTHORITY
No. 2244]
NEW DELHI, THURSDAY, MAY 22, 2025/JYAISTHA 1, 1947
3373 GI/2025
MINISTRY OF HEALTH AND FAMILY WELFARE
(Department of Health and Family Welfare)
NOTIFICATION
New Delhi, the 22nd May, 2025
S.O. 2298(E). - Whereas, the Central Government is satisfied that the use of drugs formulations containing
any antimicrobials or group of antimicrobials and their formulations as listed below in animals are likely to involve
risk to Humans.
And, whereas, safer alternatives to the said drugs for animal use are available;
And, whereas, the Central Government is satisfied that it is necessary and expedient in the public interest to
prohibit the Import, manufacture, sale, and distribution of any antimicrobial medicinal products as listed below for
animal use;
Now, therefore in exercise of the powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23
of 1940), the draft notification is hereby published after consultation with the Drugs Technical Advisory Board for
information of all persons likely to be affected thereby, and notice is hereby given that the said draft notification shall
be taken into consideration on or after the expiry of a period of thirty days from the date on which the copies of the
Gazette of India containing these draft notification are made available to the public.
Objections and suggestions which may be received from any person within the period specified above will be
considered by the Central Government.
Objections and suggestions, if any, may be addressed to the Under Secretary (Drugs), Ministry of Health and
Family Welfare, Government of India, Room No. 545 A Wing, Nirman Bhavan, New Delhi -110011 or emailed at
drugsdivmohfw@gov.in.
Following antimicrobials and group of antimicrobials and their formulations for animal use: -
1. Antibiotics
i. Ureidopenicillins
ii. Ceftobiprole
iii. Ceftaroline
iv. Siderophore cephalosporins
v. Carbapenems
vi. Penems
vii. Monobactams
viii. Glycopeptides
ix. Lipopeptides
x. Oxazolidinones
xi. Fidaxomicin
xii. Plazomicin
xiii. Glycylcyclines
xiv. Eravacycline
xv. Omadacycline
2. Antivirals
i. Amantadine
ii. Baloxavir marboxil
iii. Celgosivir
iv. Favipiravir
v. Galidesivir
vi. Lactimidomycin
vii. Laninamivir
viii. Methisazone/ Metisazone
ix. Molnupiravir
x. Nitazoxanide
xi. Oseltamivir
xii. Peramivir
xiii. Ribavirin
xiv. Rimantadine
xv. Tizoxanide
xvi. Triazavirin
xvii. Umifenovir
xviii. Zanamivir
3. Antiprotozoals
i. Nitazoxanide
[F. No. X.11035/125/2024-DR]
RAJIV WADHAWAN, Adviser (Cost)